TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04134000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG
Description: 1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
Study: NCT01015352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine 75mg/sqm SQ per day for 5 days every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine 75mg/sqm SQ per day for 5 days every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta
Description: Epoetin beta : 60000U weekly SQ injections~NeoRecormon®
Study: NCT04601051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTLA-2001
Description: A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTLA-2001
Description: A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTLA-2001
Description: A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTLA-2001
Description: A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTLA-2001
Description: A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
Study: NCT03898661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase histiolyticum
Description: local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
Study: NCT03951246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive and Motor Training
Description: In the first phase of the trial, all participants (patients and healthy children) will complete cognitive and motor functions assessment.~Then the sample of patients who have cognitive/motor impairment will be randomized to an either Intervention or Control group.~In the second phase of the trial, survivors in the Intervention Group will receive 6 sessions of cognitive and motor training during two weeks, and survivors in Control Group will undergo .....~After this treatment phase, motor and cognitive functions assessment will be conducted in all patients once again.~In the third phase, the Control Group will be provided the active intervention (i.e. 6 sessions of cognitive and motor training during two weeks), while the Intervention Group engages in passive reading.~After this, motor and cognitive functions assessment will be carried out in all patients once again.
Study: NCT01067768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily review
Description: Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.~The attending physician decides withdraw or no withdraw the urinary catheter
Study: NCT02027844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cartoon
Description: Cartoon watching by children during inhalational induction of sevoflurane

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cartoon
Description: Cartoon watching by children during inhalational induction of sevoflurane

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parental presence
Description: parental presence during inhalational induction of sevoflurane
Study: NCT04610125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide,Fludarabine
Description: Drug: Cyclophosphamide,Fludarabine
Study: NCT02027844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parental presence
Description: parental presence during inhalational induction of sevoflurane
Study: NCT02181556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: injection of FOLFIRI and Aflibercept every 14 days until progression of disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: injection of FOLFIRI and Aflibercept every 14 days until progression of disease
Study: NCT04610125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis
Study: NCT04499118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT regimen
Description: Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT regimen
Description: Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP regimen
Description: Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
Study: NCT01965808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study: NCT01687491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENOXA®
Description: enoxaparine 100 UI/Kg subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LOVENOX®
Description: enoxaparine 100 UI/Kg subcutaneous injection
Study: NCT02908113

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: collection data

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: collection data
Study: NCT04499118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP regimen
Description: Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
Study: NCT02487524

Intervention type: OTHER
Group type: OTHER
Intervention: Cold water test
Description: The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.

Intervention type: OTHER
Group type: OTHER
Intervention: Cold water test
Description: The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.

Intervention type: OTHER
Group type: OTHER
Intervention: Cold water test
Description: The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.

Intervention type: OTHER
Group type: OTHER
Intervention: Autonomic nervous system monitoring
Description: The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.

Intervention type: OTHER
Group type: OTHER
Intervention: Autonomic nervous system monitoring
Description: The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.

Intervention type: OTHER
Group type: OTHER
Intervention: Autonomic nervous system monitoring
Description: The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.

Intervention type: OTHER
Group type: OTHER
Intervention: QST
Description: Quantitative sensory testing.

Intervention type: OTHER
Group type: OTHER
Intervention: QST
Description: Quantitative sensory testing.
Study: NCT02908113

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IRM

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IRM
Study: NCT02286193

Intervention type: BEHAVIORAL
Intervention: Patient clinical encounters with Community Resource Specialist (CRS)
Description: CRS will work with patients to create goals, develop action plans and link to community resources to support goals
Study: NCT00807534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratropium bromide
Description: ipratropium bromide nebulization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo nebulization

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: constant rate step test
Description: nebulization of 500ug

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: constant rate step test
Description: nebulization of 500ug

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: constant rate shuttle walk test
Description: nebulization of 500ug

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: constant rate shuttle walk test
Description: nebulization of 500ug
Study: NCT00555984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol + Remifentanil
Description: Administered intravenously during surgery for maintenance of General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane + Remifentanil
Description: the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
Study: NCT01767376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid muscle of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
Study: NCT02487524

Intervention type: OTHER
Group type: OTHER
Intervention: QST
Description: Quantitative sensory testing.
Study: NCT03165227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: Taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken orally
Study: NCT02911311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of conbercept
Description: conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
Study: NCT01957202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/levocabastine
Description: FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocabastine
Description: levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
Study: NCT01710709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 400mg or 300mg, intramuscular injections every 4 weeks.
Study: NCT01659411

Intervention type: OTHER
Intervention: Observational
Description: Yearly clinical visits
Study: NCT03698032

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Participants will consume water only

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 oz Pistachios
Description: Participants will consume water plus 1.5 oz of pistachios as the intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3.0 oz Pistachios
Description: Participants will consume water plus 3.0 oz of pistachios as the intervention
Study: NCT03741075

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BUA
Description: bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BUA
Description: bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical tranexamic acid
Description: topical application of 200ml saline contains 2 gm tranexamic acid to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
Study: NCT04151420

Intervention type: OTHER
Intervention: Remote monitoring tool (infections questionnaire) validation
Description: There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies.
Study: NCT03684343

Intervention type: OTHER
Group type: OTHER
Intervention: Filmed consultation with a dermatologist
Description: Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior.

Intervention type: OTHER
Group type: OTHER
Intervention: Filmed consultation with a dermatologist
Description: Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior.
Study: NCT01539512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idelalisib
Description: Idelalisib 150 mg tablet administered orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
Study: NCT01957202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
Study: NCT03405649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group B
Description: Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
Study: NCT04780412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
Study: NCT04395690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant Placement in the posterior mandible
Description: Surgery done in the posterior mandible with missing teeth for placing dental implants.
Study: NCT01539512

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match idelalisib
Description: Placebo to match idelalisib administered orally twice daily
Study: NCT04395690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant Placement in the posterior mandible
Description: Surgery done in the posterior mandible with missing teeth for placing dental implants.
Study: NCT02953574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: daily sleep enhancement nursing protocol
Study: NCT01426022

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition
Description: Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mood manipulation
Description: Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
Study: NCT02462720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varithena®
Description: Varithena® treatment in accordance with full prescribing information and instructions for use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varithena®
Description: Varithena® treatment in accordance with full prescribing information and instructions for use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation conducted per physicians' standard of care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation conducted per physicians' standard of care.
Study: NCT02496299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
Study: NCT01767376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid muscle of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
Study: NCT02496299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
Study: NCT00156416

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: 8 weeks of meditation training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: 8 weeks of meditation training
Study: NCT02354872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Mini-Lozenge
Description: If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Mini-Lozenge
Description: If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Mini-Lozenge
Description: If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.